Table 4.
Phase II and III randomized trials of everolimus in metastatic breast cancer

aPhase II trial.
Abbreviations: BOLERO, Breast Cancer Trials of Oral Everolimus; CB, clinical benefit (6 months without progression); CI, confidence interval; HR, hazard ratio; mPFS, median progression-free survival; mTTP, median time to progression; ORR, overall response rate; OS, overall survival; TAMRAD, Tamoxifen and RAD001.